Keyphrases
Phase I Trial
100%
Vascular Endothelial Growth Factor
100%
PD-1 Blockade
100%
Immune Checkpoint Inhibitors
100%
Recurrent Glioblastoma
100%
Bevacizumab
80%
Avelumab
80%
Immune Cells
60%
Photothermal Therapy
60%
Confidence Interval
40%
Glioblastoma
40%
Combinational Therapy
40%
Plasma Analyte
40%
Median Survival
20%
Same Patient
20%
Serious Adverse Events
20%
Treatment Modalities
20%
T Cells
20%
CD4+ T
20%
Immune Regulation
20%
Safety Profile
20%
Tolerability
20%
Am(III)
20%
Adaptive Immune Response
20%
Cellular Expression
20%
Refractory Disease
20%
Innate Immune Cells
20%
Prolonged Survival
20%
Median Progression-free Survival
20%
Programmed Death-ligand 1 (PD-L1)
20%
Biomarker Signature
20%
T Cell Infiltration
20%
Steroid Use
20%
Mutational Burden
20%
Good Safety
20%
Overall Survival Progression-free Survival
20%
IgG1 Antibody
20%
Human IgG1
20%
Survival Signature
20%
Immune Plasma
20%
PD-L1 Inhibition
20%
Medicine and Dentistry
Glioblastoma
100%
Phase I Trials
100%
Vasculotropin A
100%
Programmed Death-Ligand 1
100%
Immunocompetent Cell
80%
Bevacizumab
80%
Avelumab
80%
Cytokine
40%
Progression Free Survival
40%
T Cell
40%
Adverse Event
20%
Disease
20%
T-Helper Cell
20%
Immunomodulation
20%
Biological Marker
20%
Overall Survival
20%
Cellular Infiltration
20%
Antiserum
20%
Immunoglobulin G1 Antibody
20%
Immunology and Microbiology
Immunocompetent Cell
100%
Programmed Death-Ligand 1
100%
Bevacizumab
100%
Vasculotropin A
100%
Avelumab
100%
T Cell
50%
Cytokine
50%
Progression Free Survival
50%
Blood Plasma
25%
T-Helper Cell
25%
Immunomodulation
25%
Overall Survival
25%
Cell Infiltration
25%
Antiserum
25%
Immunoglobulin G1 Antibody
25%
Pharmacology, Toxicology and Pharmaceutical Science
Phase I Trials
100%
Glioblastoma
100%
Vasculotropin A
100%
Bevacizumab
80%
Avelumab
80%
Cytokine
40%
Progression Free Survival
40%
Adverse Event
20%
Disease
20%
Biological Marker
20%
Overall Survival
20%
Tolerability
20%
Immunoglobulin G1 Antibody
20%